Low serum hepcidin in patients with autoimmune liver diseases

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Lyberopoulou, Aggeliki ^a,c   Chachami, Georgia ^a,c   Gatselis, Nikolaos K ^a   Kyratzopoulou, Eleni ^b   Saitis, Asterios ^a   Gabeta, Stella ^a   Eliades, Petros ^b   Paraskeva, Efrosini ^a   Zachou, Kalliopi ^a   Koukoulis, George K ^a   Mamalaki, Avgi ^b   Dalekos, George N ^a   Simos, George ^a,c  

^a UNIVERSITY OF THESSALY   (Greece)

^b HELLENIC PASTEUR INSTITUTE   (Greece)

^c Cellular Immunotherapy and Molecular Immunodiagnostics   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HEPCIDIN; MESSENGER RNA; HAMP PROTEIN, HUMAN;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; AUTOIMMUNE LIVER DISEASE; BLOOD SAMPLING; CHRONIC LIVER DISEASE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEPCIDIN GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; PROTEIN BLOOD LEVEL; AGED; AUTOIMMUNE HEPATITIS; BILIARY CIRRHOSIS; BLOOD; DIFFERENTIAL DIAGNOSIS; DOWN REGULATION; GENETICS; HEPATITIS B; HEPATITIS C; LIVER; METABOLISM; NONALCOHOLIC FATTY LIVER; PATHOLOGY; SCLEROSING CHOLANGITIS;

ADULT; AGED; CHOLANGITIS, SCLEROSING; DIAGNOSIS, DIFFERENTIAL; DOWN-REGULATION; FEMALE; FERRITINS; HEPATITIS B; HEPATITIS C; HEPATITIS, AUTOIMMUNE; HEPCIDINS; HUMANS; LIVER; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84942898167     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135486     Document Type: Article

References (57)

1. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000; 480(2-3):147-50. PMID: 11034317
2. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001; 276(11):7806-10. PMID: 11113131
3. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A. 2001; 98(15):8780-5. PMID: 11447267
4. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306(5704):2090-3. PMID: 15514116
5. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell. 2010; 142(1):24-38. doi: 10.1016/j.cell.2010.06.028 PMID: 20603012
6. Pantopoulos K, Porwal SK, Tartakoff A, Devireddy L. Mechanisms of mammalian iron homeostasis. Biochemistry. 2012; 51(29):5705-24. doi: 10.1021/bi300752r PMID: 22703180
7. Ganz T. Systemic iron homeostasis. Physiol Rev. 2013; 93(4):1721-41. doi: 10.1152/physrev.00008. 2013 PMID: 24137020
8. Pietrangelo A. Hepcidin in human iron disorders: therapeutic implications. J Hepatol. 2011; 54(1):173-81. doi: 10.1016/j.jhep.2010.08.004 PMID: 20932599
9. Ruchala P, Nemeth E. The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014; 35(3):155-61. doi: 10.1016/j.tips.2014.01.004 PMID: 24552640
10. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med. 2011; 62:347-60. doi: 10.1146/annurev-med-050109-142444 PMID: 20887198
11. Steinbicker AU, Muckenthaler MU. Out of balance-systemic iron homeostasis in iron-related disorders. Nutrients. 2013; 5(8):3034-61. doi: 10.3390/nu5083034 PMID: 23917168
12. Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006; 38(5):531-9. PMID: 16604073
13. Andriopoulos B Jr., Corradini E, Xia Y, Faasse SA, Chen S, Grgurevic L, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009; 41(4):482-7. doi: 10. 1038/ng.335 PMID: 19252486
14. Muckenthaler MU. Fine tuning of hepcidin expression by positive and negative regulators. Cell Metab. 2008; 8(1):1-3. doi: 10.1016/j.cmet.2008.06.009 PMID: 18590684
15. Xia Y, Babitt JL, Sidis Y, Chung RT, Lin HY. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood. 2008; 111(10):5195-204. doi: 10.1182/blood-2007-09-111567 PMID: 18326817
16. Silvestri L, Pagani A, Nai A, De Domenico I, Kaplan J, Camaschella C. The serine protease matriptase- 2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab. 2008; 8 (6):502-11. doi: 10.1016/j.cmet.2008.09.012 PMID: 18976966
17. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007; 109(1):353-8. PMID: 16946298
18. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002; 110 (7):1037-44. PMID: 12370282
19. Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarc'h A, Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol. 2001; 116 (2):263-70. PMID: 11488074
20. Martinelli AL, Filho AB, Franco RF, Tavella MH, Ramalho LN, Zucoloto S, et al. Liver iron deposits in hepatitis B patients: association with severity of liver disease but not with hemochromatosis gene mutations. J Gastroenterol Hepatol. 2004; 19(9):1036-41. PMID: 15304122
21. Ludwig J, Hashimoto E, Porayko MK, Moyer TP, Baldus WP. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology. 1997; 112(3):882-8. PMID: 9041250
22. Rouault TA. Hepatic iron overload in alcoholic liver disease: why does it occur and what is its role in pathogenesis? Alcohol. 2003; 30(2):103-6. PMID: 12957293
23. Corengia C, Galimberti S, Bovo G, Vergani A, Arosio C, Mariani R, et al. Iron accumulation in chronic hepatitis C: relation of hepatic iron distribution, HFE genotype, and disease course. Am J Clin Pathol. 2005; 124(6):846-53. PMID: 16416733
24. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, van Tienoven D, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood. 2011; 117(25): e218-25. doi: 10.1182/blood-2011-02-337907 PMID: 21527524
25. Trombini P, Piperno A. Ferritin, metabolic syndrome and NAFLD: elective attractions and dangerous liaisons. J Hepatol. 2007; 46(4):549-52. PMID: 17316880
26. Camaschella C, Poggiali E. Towards explaining unexplained hyperferritinemia. Haematologica. 2009; 94(3):307-9. doi: 10.3324/haematol.2008.005405 PMID: 19252171
27. Tan TC, Crawford DH, Franklin ME, Jaskowski LA, Macdonald GA, Jonsson JR, et al. The serum hepcidin: ferritin ratio is a potential biomarker for cirrhosis. Liver Int. 2012; 32(9):1391-9. doi: 10.1111/j.1478- 3231.2012.02828.x PMID: 22676252
28. Fujita N, Sugimoto R, Takeo M, Urawa N, Mifuji R, Tanaka H, et al. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med. 2007; 13(1-2):97-104. PMID: 17515961
29. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014; 60 (2):392-420. doi: 10.1016/j.jhep.2013.11.003 PMID: 24331294
30. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1):167-85. doi: 10.1016/j.jhep.2012.02.010 PMID: 22436845
31. Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008; 48(1):169-76. doi: 10.1002/hep.22322 PMID: 18537184
32. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology. 2009; 50(1):291-308. doi: 10.1002/hep.22906 PMID: 19554543
33. Rigopoulou EI, Dalekos GN. Molecular diagnostics of primary biliary cirrhosis. Expert Opin Med Diagn. 2008; 2(6):621-34. doi: 10.1517/17530059.2.6.621 PMID: 23495774
34. Gabeta S, Norman GL, Liaskos C, Papamichalis PA, Zografos T, Garagounis A, et al. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J Clin Immunol. 2007; 27(4):378-87. PMID: 17514501
35. Gatselis NK, Zachou K, Norman GL, Gabeta S, Papamichalis P, Koukoulis GK, et al. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity. 2013; 46(7):471-9. doi: 10.3109/08916934.2013.801461 PMID: 23777462
36. Williamson KD, Chapman RW. Primary sclerosing cholangitis. Dig Dis. 2014; 32(4):438-45. doi: 10. 1159/000358150 PMID: 24969292
37. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53(2):372-84. doi: 10.1016/j.jhep.2010. 04.008 PMID: 20494470
38. Koliaraki V, Marinou M, Vassilakopoulos TP, Vavourakis E, Tsochatzis E, Pangalis GA, et al. A novel immunological assay for hepcidin quantification in human serum. PLoS One. 2009; 4(2):e4581. doi: 10. 1371/journal.pone.0004581 PMID: 19238200
39. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981; 1(5):431-5. PMID: 7308988
40. Gatselis NK, Georgiadou SP, Tassopoulos N, Zachou K, Liaskos C, Hatzakis A, et al. Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: a pilot study. World J Gastroenterol. 2005; 11(4):482-7. PMID: 15641130
41. Gatselis NK, Zachou K, Norman GL, Tzellas G, Speletas M, Gabeta S, et al. IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. Clin Chim Acta. 2012; 413(19- 20):1683-8. doi: 10.1016/j.cca.2012.05.015 PMID: 22643316
42. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008; 112(10):4292-7. doi: 10.1182/blood-2008-02-139915 PMID: 18689548
43. Martinelli N, Traglia M, Campostrini N, Biino G, Corbella M, Sala C, et al. Increased serum hepcidin levels in subjects with the metabolic syndrome: a population study. PLoS One. 2012; 7(10):e48250. doi: 10.1371/journal.pone.0048250 PMID: 23144745
44. Girelli D, Pasino M, Goodnough JB, Nemeth E, Guido M, Castagna A, et al. Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol. 2009; 51(5):845-52. doi: 10.1016/j.jhep.2009.06. 027 PMID: 19729219
45. Dao MC, Meydani SN. Iron biology, immunology, aging, and obesity: four fields connected by the small peptide hormone hepcidin. Adv Nutr. 2013; 4(6):602-17. doi: 10.3945/an.113.004424 PMID: 24228190
46. Huang YH, Chuang JH, Yang YL, Huang CC, Wu CL, Chen CL. Cholestasis downregulate hepcidin expression through inhibiting IL-6-induced phosphorylation of signal transducer and activator of transcription 3 signaling. Lab Invest. 2009; 89(10):1128-39. doi: 10.1038/labinvest.2009.82 PMID: 19652645
47. Detivaud L, Nemeth E, Boudjema K, Turlin B, Troadec MB, Leroyer P, et al. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood. 2005; 106 (2):746-8. PMID: 15797999
48. Barisani D, Pelucchi S, Mariani R, Galimberti S, Trombini P, Fumagalli D, et al. Hepcidin and ironrelated gene expression in subjects with Dysmetabolic Hepatic Iron Overload. J Hepatol. 2008; 49 (1):123-33. doi: 10.1016/j.jhep.2008.03.011 PMID: 18462824
49. Fujita N, Sugimoto R, Motonishi S, Tomosugi N, Tanaka H, Takeo M, et al. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J Hepatol. 2008; 49(5):702-10. doi: 10.1016/j.jhep.2008.05.014 PMID: 18620776
50. Tsochatzis E, Papatheodoridis GV, Koliaraki V, Hadziyannis E, Kafiri G, Manesis EK, et al. Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C. J Viral Hepat. 2010; 17(11):800-6. doi: 10.1111/j.1365-2893.2009.01244.x PMID: 20002304
51. Ravasi G, Pelucchi S, Trombini P, Mariani R, Tomosugi N, Modignani GL, et al. Hepcidin expression in iron overload diseases is variably modulated by circulating factors. PLoS One. 2012; 7(5):e36425. doi: 10.1371/journal.pone.0036425 PMID: 22586470
52. Silva B, Faustino P. An overview of molecular basis of iron metabolism regulation and the associated pathologies. Biochim Biophys Acta. 2015; 1852(7):1347-59. doi: 10.1016/j.bbadis.2015.03.011 PMID: 25843914
53. Chachami G, Lyberopoulou A, Kalousi A, Paraskeva E, Pantopoulos K, Simos G. Oxygen-dependent secretion of a bioactive hepcidin-GFP chimera. Biochem Biophys Res Commun. 2013; 435(4):540-5. doi: 10.1016/j.bbrc.2013.04.085 PMID: 23665013
54. Hazlett L, Wu M. Defensins in innate immunity. Cell Tissue Res. 2011; 343(1):175-88. doi: 10.1007/ s00441-010-1022-4 PMID: 20730446
55. Zhang X, Rovin BH. Beyond anemia: hepcidin, monocytes and inflammation. Biol Chem. 2013; 394 (2):231-8. doi: 10.1515/hsz-2012-0217 PMID: 23314535
56. Lang KS, Burow A, Kurrer M, Lang PA, Recher M. The role of the innate immune response in autoimmune disease. J Autoimmun. 2007; 29(4):206-12. PMID: 17904335
57. Chamaillard M, Dessein R. Defensins couple dysbiosis to primary immunodeficiency in Crohn's disease. World J Gastroenterol. 2011; 17(5):567-71. doi: 10.3748/wjg.v17.i5.567 PMID: 21350705